RU-22930
RU-22930
RU-22930 (/ˈruː ˈtwɛntiː ˈnaɪn ˈθɜːrtiː/), also known as RU 22930, is a pharmacological compound of interest in the field of medicine and pharmacology. The etymology of the term is derived from the initials of the Roussel Uclaf company that first synthesized the compound, followed by a unique numerical identifier.
Definition
RU-22930 is a synthetic, non-steroidal antiandrogen that was developed for potential use in the treatment of prostate cancer and other androgen-dependent conditions. It acts by blocking the effects of androgens (male hormones) in the body.
Pharmacology
In pharmacological terms, RU-22930 is classified as an antiandrogen. Antiandrogens are substances that inhibit the biological effects of androgen hormones in the body. They do this by blocking the androgen receptors, which are found in various tissues throughout the body.
Clinical Use
RU-22930 has been studied for potential use in the treatment of prostate cancer and other androgen-dependent conditions. However, as of now, it is not approved for clinical use.
Related Terms
External links
- Medical encyclopedia article on RU-22930
- Wikipedia's article - RU-22930
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski